PT  - JOURNAL ARTICLE
AU  - Sam Palmer
AU  - Nik Cunniffe
AU  - Ruairí Donnelly
TI  - Risk of COVID-19 hospitalisation rises exponentially with age, inversely proportional to T-cell production
AID  - 10.1101/2020.08.25.20181487
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.25.20181487
4099  - http://medrxiv.org/content/early/2020/08/31/2020.08.25.20181487.short
4100  - http://medrxiv.org/content/early/2020/08/31/2020.08.25.20181487.full
AB  - Here we report that COVID-19 hospitalisation rates follow an exponential relationship with age, increasing by 4.5% per year of life (95% CI: 4.2-5.2%). This mirrors the exponential decline of thymus volume and T-cell production (decreasing by 4.5% per year). COVID-19 can therefore be added to the list of other diseases with this property, including those caused by MRSA, West Nile virus, Streptococcus Pneumonia and certain cancers, such as chronic myeloid leukemia and brain cancers. In addition, incidence of severe disease and mortality due to COVID-19 are both higher in men, consistent with the degree to which thymic involution (and the decrease in T-cell production with age) is more severe in men compared to women. For under 20s, COVID-19 incidence is remarkably low. A Bayesian analysis of daily hospitalisations, accounting for contact-based and environmental transmission, indicates that non-adults are the only age group to deviate significantly from the exponential relationship. Our model fitting suggests under 20s have 53-77% additional immune protection beyond that predicted by strong thymus function alone. We found no evidence for differences between age groups in susceptibility to overall infection, or, relative infectiousness to others. The simple inverse relationship between risk and thymus size we report here suggests that therapies based on T-cell mechanisms may be a promising target.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSP is funded by Wellcome Trust and NC and RD report no relevant funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAdditional code can be found at https://github.com/samIndeed/COVID https://github.com/samIndeed/COVID